Business Model

GNI Group, as the corporate headquarters, operates across four core areas—investment, Pharma, Biotech, and Medtech —to secure geographically and operationally diversified revenue streams. By doing so, the Group mitigates risks and enhances synergies through cross-border licensing-out, partnerships, and collaborations, with the aim of further expanding its global revenue base.

GNI Group (Headquarter)

GNI Group serves as the global strategic hub, playing a central role in investment, partnerships, and business development.
An Investment Committee has been established to drive strategic collaborations within the Group and to explore new business opportunities that will contribute to the growth of the GNI Group.

Pharma Business

As the global strategic hub of the GNI Group, is a fully integrated organization focused on the fibrosis of organs, covering all functions from research and development to manufacturing and sales. It operates a nationwide distribution network in China and has a sales and marketing team of approximately 400 personnel.
Gyre Pharmaceuticals was the first in China to develop and launch a treatment for idiopathic pulmonary fibrosis (IPF), Etuary®, which has been available on the Chinese market since 2014. The company aims to achieve continued revenue growth by expanding approved indications and strengthening its product lineup.

Gyre Pharmaceuticals is also engaged in the research and development of innovative pharmaceuticals, including F351, a treatment for liver fibrosis caused by hepatitis B, which has been designated as a “Breakthrough Therapy.”

Leveraging its extensive experience from in-house development to commercialization, Gyre will continue to expand and strengthen its development pipeline.

Biotech Business

Cullgen, a subsidiary of the Group, has independently developed a proprietary technology called uSMITE™ (ubiquitin-mediated, Small Molecule Induced Target Elimination), which enables the degradation and removal of so-called “undruggable targets” — proteins that have been difficult to control with conventional small molecule therapies. This breakthrough opens up new possibilities in drug discovery.

By designing small molecule compounds that link disease-related target proteins to the cell’s ubiquitin-proteasome system (UPS), uSMITE™ allows for the selective degradation of these proteins within the cell.

Using the uSMITE™ platform, Cullgen is pursuing novel therapeutic approaches for diseases that have been difficult to treat with traditional methods. The company is particularly focused on the areas of cancer, inflammation, and pain, and is advancing the development of next-generation therapeutics across a broad range of indications.

Medtech Business

As a third core business following our pharmaceutical and drug discovery operations, we are engaged in the medtech business, centered around our subsidiaries Berkeley Advanced Biomaterials LLC and Berkeley Biologics LLC.

The biomaterials market is characterized by long product life cycles and industry stability, enabling steady cash flow generation.
 By collaborating with Osderma Medical, an equity-method affiliate, we aim to expand the revenue of our medtech business by applying biomaterials technologies to the aesthetic and cosmetic fields.